glp-1 cardiovascular outcomes 2025 news Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies The cardiovascular effects of GLP-1

Healthy Weight and Growth

Blevins JE, Schwartz MW, Baskin DG

The future directions and challenges of new small-molecule GLP-1R agonists, such as danuglipron, are multifaceted

Other research reveals metabolic benefits such as lowered cholesterol and blood pressure could persist even after quitting the drug

It depends on your plan and diagnosis: Most Illinois insurance plans cover GLP-1s for diabetes (Ozempic, Mounjaro.) Coverage for obesity (Wegovy, Zepbound) varies significantly Blue Cross Blue Shield of Illinois: Variable by plan, often requires BMI 30+ and prior weight loss attempts UnitedHealthcare: Many plans exclude obesity medications entirely Aetna: Some plans cover with prior authorization Illinois Medicaid: Covers for diabetes, limited obesity coverage We help with prior authorizations and appeals

In addition, recurrent hypoglycemia exacerbates the defective responses to subsequent hypoglycemia, thus leading to a vicious circle of reduced awareness, increased vulnerability and further episodes of hypoglycemia (Figure 13.7)